The pharmaceutical company Noramco, headquartered on the Wilmington riverfront, has signed a letter of intent with Teewinot Life Sciences to produce pharmaceutical-grade cannabinoids, the chemical compounds in cannabis flowers and a component of marijuana. 

The goal is to provide a source for large quantities of "cannabinoid-based reference materials" outside of plant extraction, according to Jeffrey M. Korentur, president and CEO of Tweewinot Life Sciences.

Noramco plans to use the process to enter the growing market surrounding cannabis and cannabis-derived products.

"Combining Teewinot's CannSynthesis technology with Noramco's controlled substance manufacture and distribution expertise allows us to serve a fast emerging market space," said James Mish, President and CEO of Noramco.